Oncology – Lung
M-A | Sensitivity and complications of thoracentesis and thoracoscopy for the diagnosis of malignant pleural effusions
27 Jan, 2023 | 12:11h | UTC
Review | Lung cancer screening: new evidence, updated guidance
26 Jan, 2023 | 12:08h | UTCLung cancer screening: New evidence, updated guidance – Journal of Family Practice
Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Guideline for diagnosis, treatment and follow-up
23 Jan, 2023 | 13:32h | UTC
Post-trial follow-up | Efficacy and safety of first-line lorlatinib vs. crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer
19 Jan, 2023 | 13:49h | UTCEfficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Original Study: First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer – New England Journal of Medicine
Commentary on Twitter
NEW—Updated, long-term data from the CROWN study show durable benefit of lorlatinib vs crizotinib in pts w/ treatment-naive, ALK-positive #NSCLC
From Prof Benjamin Solomon & colleagues https://t.co/jfOEMRNEgl pic.twitter.com/SBaRCBEGIy
— The Lancet Respiratory Medicine (@LancetRespirMed) December 19, 2022
A deep learning model may predict future lung cancer risk from a single low-dose chest CT
18 Jan, 2023 | 14:00h | UTCNews Release: Artificial intelligence tool developed to predict risk of lung cancer – Massachusetts General Hospital
Commentary: AI tool predicts lung cancer without radiologists or clinical histories – Health Imaging
RCT | High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer
15 Jan, 2023 | 19:51h | UTCHigh-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538 – Journal of Clinical Oncology (link to abstract – $ for full-text)
ASCO Living Guideline | Therapy for stage IV non–small-cell lung cancer without driver alterations
12 Jan, 2023 | 13:12h | UTCEditorial: ASCO Living Guidelines: The Next Frontier
ASCO Living Guideline | Therapy for stage IV non–small-cell lung cancer with driver alterations
12 Jan, 2023 | 13:13h | UTCEditorial: ASCO Living Guidelines: The Next Frontier
RCT | Durvalumab with or without Tremelimumab plus chemotherapy for metastatic non–small-cell lung cancer.
14 Dec, 2022 | 14:47h | UTCCommentary: Adding Tremelimumab and Durvalumab to Chemo Improves PFS, OS in mNSCLC – Cancer Therapy Advisor
Commentary on Twitter
🙌 POSEIDON: 1L tremelimumab + durvalumab + chemotherapy significantly improve progression-free and overall survival in stage IV non small cell #LungCancer 👉 https://t.co/d6causVZ4u #JCO #ImmunoOnc #Immunotherapy #LCSM @MLJohnsonMD2 #NSCLC pic.twitter.com/aIkCwSAwFe
— Journal of Clinical Oncology (@JCO_ASCO) December 3, 2022
Cohort Study | Association of sinoatrial node radiation dose with atrial fibrillation and mortality in patients with lung cancer.
3 Nov, 2022 | 13:39h | UTCAssociation of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)
Commentaries:
Incidental sinoatrial node irradiation may increase AF risk in lung cancer – medwire News
Commentary on Twitter
Incidental irradiation to the sinoatrial node may cause new-onset #AtrialFibrillation & decrease overall survival in patients with #LungCancer receiving concurrent #chemoradiotherapy. https://t.co/hPVSnhp11R #RadOnc #LCSM
— JAMA Oncology (@JAMAOnc) September 27, 2022
NICE Guideline Update | Lung cancer: diagnosis and management.
2 Nov, 2022 | 14:28h | UTCLung cancer: diagnosis and management – National Institute for Health and Care Excellence
Post-trial follow-up | Pembrolizumab vs. chemotherapy as first-line therapy in PD-L1-expressing non–small-cell lung cancer.
31 Oct, 2022 | 13:39h | UTC
RCT | Lurbinectedin plus Doxorubicin are no better than physician’s choice of chemotherapy in relapsed small-cell lung cancer.
20 Oct, 2022 | 12:19h | UTCCombination lurbinectedin and doxorubicin versus physician’s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW—Lurbinectedin + doxorubicin did not improve overall survival vs control in relapsed SCLC., but did show a favourable haematological safety profile
ATLANTIS trial from Prof Luis Paz-Ares & colleagues https://t.co/oF57GJx7u1 pic.twitter.com/8aoqTqXUl7
— The Lancet Respiratory Medicine (@LancetRespirMed) October 17, 2022
Post-trial follow-up | Nivolumab plus ipilimumab vs. chemotherapy as first-line treatment for metastatic non-small cell lung cancer.
19 Oct, 2022 | 14:17h | UTCFive-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227 – Journal of Clinical Oncology (link to abstract – $ for full-text)
Original Study: #ESMO19 –Randomized Trial: Improved Overall Survival with Combined Immunotherapy for Advanced Non–Small-Cell Lung Cancer
RCT | Toripalimab plus chemotherapy for patients with treatment-naive advanced non–small-cell lung cancer.
11 Oct, 2022 | 13:31h | UTC
RCT | Pembrolizumab vs. placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer.
29 Sep, 2022 | 13:22h | UTCPembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Adjuvant Pembrolizumab in Patients With Completely Resected Stage IB to IIIA NSCLC – The ASCO Post
Adjuvant Pembrolizumab Prolongs DFS in Resected Non-Small Cell Lung Cancer – Cancer Therapy Advisor
Commentary on Twitter
New Research in @TheLancetOncol—Pembrolizumab improves disease-free survival vs placebo in completely resected, PD-L1-unselected, stage IB–IIIA #NSCLC
From Prof Mary O’Brien & colleagues https://t.co/Azqb8WTOwp pic.twitter.com/141bhAPtg5
— The Lancet Respiratory Medicine (@LancetRespirMed) September 13, 2022
RCT | First-Line Serplulimab vs. placebo added to chemotherapy in patients with extensive-stage small cell lung cancer.
28 Sep, 2022 | 13:41h | UTCEffect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
RCT | Efficacy and safety of carboplatin with nab-paclitaxel vs. docetaxel in older patients with squamous non-small-cell lung cancer.
14 Sep, 2022 | 13:00h | UTC
Commentary on Twitter
New research: in a ph3 RCT pts aged 70 yrs and older with squamous non-small-cell #lungcancer, overall survival was significantly longer with #carboplatin & nab-paclitaxel vs #docetaxel
👉https://t.co/qOuaVpO61f pic.twitter.com/TSnMguOkoR— The Lancet Healthy Longevity (@LancetLongevity) December 9, 2021
RCT | Dexamethasone is not effective for the treatment of dyspnea in patients with cancer and increases the risk of adverse events.
13 Sep, 2022 | 13:22h | UTCEffect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial – The Lancet Oncology (free for a limited period)
Commentary on Twitter
Our phase III randomized study, published in Lancet Oncology today, showed high-dose steroid didn’t improve SOB and should not be used routinely in pts with lung ca for SOB palliation. My personal link in Lancet Oncology article ⁰https://t.co/Mj0AAzMujB pic.twitter.com/FMG7csHZsn
— Joe Y Chang (@JoeChangMD) September 7, 2022
RCT | Anatomical segmentectomy vs. standard lobectomy for non-small cell lung cancer up to 2 cm.
6 Sep, 2022 | 14:28h | UTCRelated:
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
RCT | Cemiplimab plus chemotherapy vs. chemotherapy alone in non-small cell lung cancer.
29 Aug, 2022 | 12:08h | UTC
Commentary on Twitter
Results from EMPOWER-Lung 3 demonstrate increased overall survival with #cemiplimab plus platinum-doublet #chemotherapy compared with cemiplimab as first-line treatment in patients with advanced non-small cell #LungCancer, irrespective of #PD-L1 expressionhttps://t.co/ojCDeivKzC
— Nature Medicine (@NatureMedicine) August 25, 2022
RCT | Nivolumab vs. nivolumab plus docetaxel for previously treated advanced or recurrent immune checkpoint inhibitor-naïve non-small-cell lung cancer.
25 Aug, 2022 | 11:48h | UTC
M-A | Erlotinib plus bevacizumab vs. erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer.
22 Aug, 2022 | 12:04h | UTC
RCT | Chest CT scan plus x-ray vs. chest x-ray for the follow-up of completely resected non-small-cell lung cancer.
16 Aug, 2022 | 13:50h | UTCChest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Totally unexpected! After resection of early NSCLC in 1775 pts, follow-up by ct-scan did not improve survival vs a simple chest X-Rays! We should ALWAYS questioned our practice. Amazing work from Virginie Westeel @barlesi @IFCTlung https://t.co/iMFGtpkQcF
— Benjamin Besse (@BenjaminBesseMD) August 12, 2022
Long-term results of a RCT | Gefitinib-alone vs. Gefitinib plus chemotherapy for non–small-cell lung cancer with mutated EGFR.
15 Aug, 2022 | 11:44h | UTC